Showing 715 results
-
Media Release /New Cosentyx® (secukinumab) data from REPLENISH, largest ever global Phase III trial in polymyalgia rheumatica, to be highlighted in oral session New ianalumab interim results from Sjögren’s Phase…
-
Media Release /Improved radiographic progression-free survival (rPFS) regardless of disease volume or metastatic presentation achieved with Pluvicto plus standard of care (ARPI + ADT) in PSMAddition Consistent…
-
Media Release /Late-breaking Phase III IgAN data for Vanrafia ALIGN and Fabhalta APPLAUSE-IgAN studies to be presented 124-week Phase I/II zigakibart data evaluating treatment efficacy and safety in IgAN will be…
-
Media Release /Pluvicto® PSMAddition oral presentation to highlight efficacy outcomes by disease volume and de novo/recurrent metastatic hormone-sensitive prostate cancer Kisqali® NATALEE oral presentation to…
-
Media Release /More durable, deeper PSA response in patients treated with Pluvicto plus standard of care (ARPI + ADT) vs. SoC alone in PSMAddition Deep PSA reduction higher in patients receiving Pluvicto…
-
Media Release /US Under Secretary of Commerce Jeffrey Kessler, Texas State Senator Brent Hagenbuch, Novartis leadership mark expansion of company’s coast-to-coast RLT manufacturing network – the largest in the…
-
Media Release /At one-year mark, company has progressed all components of US investment plan to support delivery of innovative medicines to US patientsNew active pharmaceutical ingredients facility in North…
-
Media Release /Coartem® (artemether-lumefantrine) Baby is the first and only malaria treatment for newborns and young infants, closing long-standing treatment gap WHO prequalification key milestone for donor-funded…
-
Media Release /Strengthens three community health models spanning community‑embedded care, earlier intervention and data‑driven population healthScales program footprint from 11 countries to more than 30 by 2030,…
-
Media Release /Fabhalta lowered likelihood of progression to kidney failure by 43% in APPLAUSE-IgAN study1 40.7% of patients on Fabhalta demonstrated sustained reduction of protein in urine over two years1…
